Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: A randomised phase II study

Abstract Background The aim of this study was to examine the effect of magnesium supplementation on nephrotoxicity accompanying standard cisplatin-based chemotherapy in patients with epithelial ovarian cancer (EOC). Patients and methods A double-blind, placebo-controlled, randomised study was conduc...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2008-11, Vol.44 (17), p.2608-2614
Main Authors: Bodnar, Lubomir, Wcislo, Gabriel, Gasowska-Bodnar, Agnieszka, Synowiec, Agnieszka, Szarlej-Wcisło, Katarzyna, Szczylik, Cezary
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Biological and medical sciences
Cisplatin
Cisplatin - administration & dosage
Double-Blind Method
Female
Hematology, Oncology and Palliative Medicine
Humans
Kidney Diseases - chemically induced
Kidney Diseases - prevention & control
Magnesium
Magnesium - therapeutic use
Magnesium Sulfate - therapeutic use
Medical sciences
Middle Aged
Ovarian cancer
Ovarian Neoplasms - drug therapy
Paclitaxel - administration & dosage
Pharmacology. Drug treatments
Renal Agents - therapeutic use
Renal function
Side effect
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background The aim of this study was to examine the effect of magnesium supplementation on nephrotoxicity accompanying standard cisplatin-based chemotherapy in patients with epithelial ovarian cancer (EOC). Patients and methods A double-blind, placebo-controlled, randomised study was conducted in which study arm magnesium sulphate (5 g) was administered before each course of standard chemotherapy with paclitaxel (135 mg/m2 /24 h) plus cisplatin (75 mg/m2 ) every 3 weeks in patients with EOC. Magnesium subcarbonate (500 mg), three times per day orally, was administered during the treatment intervals. The control arm was administered a placebo instead of both magnesium salts. Magnesium serum levels (sMg) and GFR markers: serum levels of creatinine (sCr), Cockroft–Gault (ClCG) and Modification Diet of Renal Disease (MDRD) formulae were recorded before each cycle, and 3 weeks after the sixth course. Results 41 EOC patients were randomised and 40 were eligible. sMg varied significantly between the supplemented and placebo groups ( p
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2008.08.005